(A.T.C.C. Accession Number PTA-815) and an antigen binding fragment thereof, wherein the antibody binds ouabain and binding of the antibody to ouabain is not inhibited by about 100μM digoxin.

6. (Amended) A hybridoma cell line which produces a monoclonal antibody selected from the group consisting of: 1-10 (A.T.C.C. Accession Number PTA-814), 7-1 (A.T.C.C. Accession Number PTA-813), 8E4 (A.T.C.C. Accession Number PTA-815), a monoclonal antibody having the same binding specificity as 1-10 (A.T.C.C. Accession Number PTA-814), 7-1 (A.T.C.C. Accession Number PTA-813) or 8E4 (A.T.C.C. Accession Number PTA-815), and an antigen binding fragment thereof, wherein the antibody binds ouabain and binding of the antibody to ouabain is not inhibited by about 100μM digoxin.

B4

38. (Amended) A pharmaceutical composition comprising a monoclonal antibody or antigen binding fragment thereof having binding specificity for ouabain, wherein binding of the antibody or antigen binding fragment to ouabain is not inhibited by about 100μM of digoxin, and a pharmaceutical acceptable carrier.

Please add new Claims 40-55.

40. (New) A monoclonal antibody or antigen binding fragment thereof having binding specificity for ouabain, wherein binding of the antibody or antigen binding fragment to ouabain is not inhibited by about 50μM of digoxin.

B5

41. (New) The monoclonal antibody of Claim 40 wherein the antibody is 5A12 (A.T.C.C. Accession Number PTA-812) or an antigen binding fragment thereof.

42. (New) A monoclonal antibody or antigen binding fragment thereof having the same binding specificity as monoclonal antibody 5A12 (A.T.C.C. Accession Number PTA-

812), wherein the antibody binds ouabain and binding of the antibody to ouabain is not inhibited by about 50μM digoxin.

43. (New) A hybridoma cell line which produces a monoclonal antibody selected from the group consisting of: 5A12 (A.T.C.C. Accession Number PTA-812), a monoclonal antibody having the same binding specificity 5A12 (A.T.C.C. Accession Number PTA-812), and an antigen binding fragment thereof, wherein the antibody binds ouabain and binding of the antibody to ouabain is not inhibited by about 50μM digoxin.

44. (New) A pharmaceutical composition comprising a monoclonal antibody or antigen binding and an antigen binding fragment thereof fragment thereof having binding specificity for ouabain, wherein binding of the antibody or antigen binding fragment to ouabain is not inhibited by about 100μM of digoxin, and a pharmaceutical acceptable carrier.

45. (New) A monoclonal antibody comprising 1-10 (A.T.C.C. Accession Number PTA-814).

46. (New) A monoclonal antibody comprising 7-1 (A.T.C.C. Accession Number PTA-813).

47. (New) A monoclonal antibody comprising 8E4 (A.T.C.C. Accession number PTA-815).

48. (New) A monoclonal antibody comprising 5A12 (A.T.C.C. Accession Number PTA-812).

49. (New) A monoclonal antibody or antigen binding fragment thereof having the same binding specificity as 1-10 (A.T.T.C. Accession Number PTA-814).

50. (New) A monoclonal antibody or antigen binding fragment thereof having the same binding specificity as 7-1 (A.T.C.C. Accession Number PTA-813).

51. (New) A monoclonal antibody or antigen binding fragment thereof having the same binding specificity as 8E4 (A.T.C.C. Accession Number PTA-815).

52. (New) A hybridoma cell line which produces monoclonal antibody 1-10 (A.T.C.C. Accession Number PTA-814) or an antigen binding fragment thereof.

53. (New) A hybridoma cell line which produces monoclonal antibody 7-1 (A.T.C.C. Accession Number PTA-813) or an antigen binding fragment thereof.

54. (New) A hybridoma cell line which produces monoclonal antibody 8E4 (A.T.C.C. Accession Number PTA-815) or an antigen binding fragment thereof.

55. (New) A hybridoma cell line which produces monoclonal antibody 5A12 (A.T.C.C. Accession Number PTA-812) or an antigen binding fragment thereof.

REMARKS

Applicants would like to thank the Examiner for her careful reading of the subject specification.

Claim Amendments

Claims 1 and 38 have been amended to further clarify that the claimed monoclonal antibody or antibody binding fragment does not cross react with100μM of digoxin. Support for these amendment can be found, for example, on page 22, line 20 of the specification. Claims 2, 5 and 6 have been amended to recite the ATCC depository numbers for the monoclonal antibodies. Support for the amendment can be found, for example, on page 8, lines 17-21 of the specification.

New Claims 40-44, which are directed to a monoclonal antibody or antigen binding fragment thereof having binding specificity for ouabain, wherein the antibody or antigen binding